Email
Print
MicroRNA Therapies Market Overview:
MicroRNA Therapies Market size is estimated to reach $7 billion by 2030, growing at a CAGR of 12.5% during the forecast period 2024-2030. The rapid development and regulatory approval of emerging miRNA-based therapeutics led to the growth of the MicroRNA Therapies Market. This trend is expected to boost the growth of the MicroRNA Therapies Market during the forecast period.
MicroRNA (miRNA) therapies refer to a class of therapeutic interventions that involve the modulation of microRNA levels in the body to treat or manage various diseases. MicroRNAs are small RNA molecules that play a crucial role in regulating gene expression. The road to approval for miRNA therapies appears to be faster than that of conventional drugs, potentially leading to quicker advancements in treatment options. This trend signifies the growing recognition of miRNA therapies as a viable and efficient approach in molecular medicine. These factors positively influence the microRNA Therapies industry outlook during the forecast period.
Market Snapshot:
--
MicroRNA Therapies Market - Report Coverage:
The “MicroRNA Therapies Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the MicroRNA Therapies Market.
| Attribute | Segment |
|---|---|
|
By Product Type |
|
|
By Technology |
|
|
By Application |
|
|
By End-User |
|
|
By Geography |
|
COVID-19 / Ukraine Crisis - Impact Analysis:
• The Covid-19 epidemic has had a complex and multifaceted impact on the MicroRNA Therapies market's growth trajectory. On the one hand, the pandemic has highlighted the critical need for novel therapeutic techniques, particularly those based on microRNA, to address the virus's problems. This has the potential to increase attention and funding in the development of MicroRNA Therapies as a promising antiviral therapy route. The pandemic, on the other hand, has changed the overall healthcare landscape, diverting resources and attention to immediate and pressing public health concern. Clinical trials, research, and development activities linked to MicroRNA Therapies may have been delayed or reallocated, slowing progress in this sector. Furthermore, the economic consequences of the pandemic may have influenced financing availability and investment decisions, hence influencing the whole funding ecosystem for biotechnological and pharmaceutical endeavors, including MicroRNA Therapies. Despite these obstacles, the pandemic's enhanced awareness of the necessity of targeted and precision medicine may position MicroRNA Therapies for further growth and investigation in the post-Covid future.
● The ongoing Russia-Ukraine conflict has cast a shadow on various industries, including the field of microRNA therapies. The cumulative impact of the Russia-Ukraine conflict, on the other hand, is expected to have major long-term implications on the worldwide microRNA market. Unfortunately, the available search results do not provide particular facts on how the war directly affected the expansion of MicroRNA Therapies. It's important to highlight that geopolitical conflicts can disrupt supply chains, disrupt research collaborations, and undermine investor confidence, thus hindering the development and commercialization of innovative medical innovations like microRNA therapies. However, further in-depth study and industry reports focused on this specific component may be required for exact insights into the war's immediate impact.
Key Takeaways:
● North-America Region Contributes to the Highest Market Share
Geographically, in the global microRNA Therapies market share, North-America has highest share 35% in 2023 due to its dynamic and creative healthcare ecosystem. The region has a strong network of R&D centers, which include prestigious institutions, universities, and cutting-edge biotechnology firms. These entities actively contribute to the investigation of innovative therapeutic routes, such as the creation of microRNA-based therapies.
The United States, in particular, stands out for its strong biotechnology and pharmaceutical industries, which are distinguished by substantial investments in research and development. This dedication extends to the study of microRNAs, their functions in numerous diseases, and the therapeutic promise they hold. The region's concentration on creating an environment conducive to scientific inquiry and technical developments accelerates progress in MicroRNA Therapies, establishing North America as a significant role in the worldwide expansion of this burgeoning medical sector.
● Cancer Segment to Register the Fastest Growth
In the MicroRNA Therapies Market analysis, the Cancer segment is estimated to grow with the fastest CAGR of 13.8% during the forecast period 2024-2030. MicroRNA treatments, which offer a targeted and personalized approach to cancer treatment, have showed tremendous promise in the field of oncology. Because of the high prevalence of cancer in the region, there is a greater emphasis on creating novel and effective therapy options. North American academic institutes and biotechnology firms have been at the forefront of utilizing microRNAs' potential to alter gene expression and regulate key pathways involved in cancer progression.
The delicate roles that microRNAs play in diverse forms of cancer, impacting cellular processes such as proliferation, apoptosis, and metastasis, are becoming more understood. This understanding has motivated considerable research efforts to discover individual microRNAs linked to various cancer types and create medicines that can modify these molecules to combat the disease.
● The Academic and Government Research Institutes Dominates the Growth of the Market
According to the MicroRNA Therapies Market forecast, the Academic and Government Research Institutes sector is estimated to register the fastest growth during the forecast period with a CAGR of 13.9% during forecast period 2024-2030 due to their contributions to scientific understanding, innovation, and regulatory advancements. These institutes serve as cutting-edge research hubs, laying the groundwork for the development of MicroRNA-based therapeutics. In these situations, researchers frequently investigate the complex mechanisms of MicroRNA regulation, discover new therapeutic targets, and undertake preclinical studies to validate the efficacy and safety of MicroRNA therapeutics. Their discoveries not only improve our understanding of the underlying biological mechanisms but also provide useful information for optimizing therapeutic therapies.
In addition, academia and government organizations routinely engage with commercial partners and pharmaceutical companies to put research discoveries into practical medicinal applications. This collaborative strategy hastens the development and commercialization of MicroRNA therapeutics, enabling a dynamic ecosystem in which scientific discoveries move effortlessly from the laboratory to clinical settings. In addition to doing research, these institutes play an important role in developing regulatory frameworks and recommendations. They collaborate with regulatory bodies to develop standardized processes for the evaluation and approval of MicroRNA therapies, ensuring that these innovative treatments meet severe safety and efficacy criteria.
● Growing Advancements in Molecular Biology and Genomics
Significant advances in molecular biology and genomics are propelling the expansion of the MicroRNA Therapies market, leading to a better understanding of the complex regulatory roles that microRNAs play in gene expression. Researchers are identifying distinct microRNA profiles linked to a variety of disorders, providing significant insight into possible treatment targets. Pharmaceutical companies are more positioned to produce highly targeted and effective MicroRNA therapeutics as the information base grows. This enhanced understanding of disease molecular pathways improves the precision and therapeutic potential of MicroRNA-based therapies, propelling the market ahead.
Furthermore, advances in high-throughput sequencing methods have sped up the detection of dysregulated microRNAs in diseased circumstances. This richness of genomic data not only benefits in target discovery but also in the creation of personalized MicroRNA therapies customized to unique patient profiles, which contributes to market growth.
● Technological Advancements in RNA-based Therapeutics
Technological improvements in RNA-based treatment platforms are a key driver of the MicroRNA Therapies market. Researchers and biopharmaceutical businesses are making significant progress in overcoming past barriers to the delivery and stability of RNA molecules, especially microRNAs. Bioavailability and targeted delivery of MicroRNA therapies to specific tissues or cells are improved by advancements in delivery technologies such as lipid nanoparticles and viral vectors. Nucleotide modification strategies help to improve MicroRNA stability and efficacy even more. These technological advances not only improve the pharmacokinetics of MicroRNA treatments, but also their safety characteristics. As the science of RNA treatments advances, the attractiveness of MicroRNA-based interventions grows, propelling the market's rise.
● Delivery Challenges and Tissue Specificity restrain the growth of the MicroRNA Therapies Market
The effective delivery of microRNAs to target tissues is one of the key problems confronting the MicroRNA Therapies industry. MicroRNAs are intrinsically fragile and can be rapidly destroyed in the bloodstream, making sufficient quantities at the target areas of action difficult to achieve. Furthermore, ensuring that microRNAs are delivered to the appropriate tissues while avoiding off-target effects remains a substantial challenge. The study of reliable and targeted delivery mechanisms, such as nanoparticles or viral vectors, is underway. Overcoming these delivery issues is critical for optimizing MicroRNA therapeutic efficacy and realizing their full promise in clinical settings.
MicroRNA Therapies Market Share (%) By Region, 2023
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the MicroRNA Therapies Market. The top 10 companies in this industry are listed below:
- Thermo Fisher Scientific, Inc. (miRNA Profiling with Real-Time PCR)
- Regulus Therapeutics (RGLS8429)
- Horizon Discovery Ltd. (miRIDIAN microRNA Mimic, shMIMIC Lentiviral microRNA)
- QIAGEN (miRCURY LNA miRNA PCR Assays, miScript miRNA Mimics)
- GeneCopoeia (microRNA Solutions)
- New England Biolabs (Universal miRNA Cloning Linker)
- Quantabio (qScript® microRNA cDNA Synthesis Kit)
- BioGenex (miRNA Probes, Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel)
- SeqMatic LLC (miRNA & Small RNA Sequencing Services)
- Sistemic Scotland Limited (SistemRNA™ : Drug Repositioning & Re-purposing in vitro)
Scope of Report:
| Report Metric | Details |
|---|---|
|
Base Year Considered |
2023 |
|
Forecast Period |
2024–2030 |
|
CAGR |
12.5% |
|
Market Size in 2030 |
$7 billion |
|
Segments Covered |
Product Type, Technology, Application, End-User and Region |
|
Geographies Covered |
North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa). |
|
Key Market Players |
|
For more Lifesciences and Healthcare Market reports, please click here
1. MicroRNA Therapies Market - Overview
1.1. Definitions and Scope
2. MicroRNA Therapies Market - Executive Summary
3. MicroRNA Therapies Market - Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. MicroRNA Therapies Market - Start-up Companies Scenario
4.1. Key Start-up Company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Venture Capital and Funding Scenario
5. MicroRNA Therapies Market – Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. MicroRNA Therapies Market - Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.4.1. Bargaining Power of Suppliers
6.4.2. Bargaining Powers of Customers
6.4.3. Threat of New Entrants
6.4.4. Rivalry Among Existing Players
6.4.5. Threat of Substitutes
7. MicroRNA Therapies Market – Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. MicroRNA Therapies Market – by Product Type (Market Size – $Million/$Billion)
8.1. miRNA Mimics
8.2. Antagomirs or Inhibitors
9. MicroRNA Therapies Market – by Technology (Market Size – $Million/$Billion)
9.1. Microarrays
9.2. Next Generation Sequencing (NGS)
9.3. Quantitative Real-Time PCR (qRT-PCR)
9.4. Northern Blotting
9.5. In Situ Hybridization (ISH)
10. MicroRNA Therapies Market – by Technology (Market Size – $Million/$Billion)
10.1. Cancer
10.2. Infectious Diseases
10.3. Immunological Disorder
10.4. Cardiovascular Diseases
10.5. Neurological Diseases
10.6. Other
11. MicroRNA Therapies Market – by End-User (Market Size – $Million/$Billion)
11.1. Biotechnology &Pharmaceutical Companies
11.2. Academic & Government Research Institutes
11.3. Others
12. MicroRNA Therapies Market – by Geography (Market Size – $Million/$Billion)
12.1. North America
12.1.1. The U.S.
12.1.2. Canada
12.1.3. Mexico
12.2. Europe
12.2.1. UK
12.2.2. Germany
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. South Korea
12.3.5. Australia & New Zealand
12.3.6. Rest of Asia-Pacific
12.4. South America
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Chile
12.4.4. Colombia
12.4.5. Rest of South America
12.5. Rest of the World
12.5.1. Middle East
12.5.2. Africa
13. MicroRNA Therapies Market – Entropy
14. MicroRNA Therapies Market – Industry/Segment Competition Landscape
14.1. Market Share Analysis
14.1.1. Market Share by Product Type – Key Companies
14.1.2. Market Share by Region – Key Companies
14.1.3. Market Share by Country – Key Companies
14.2. Competition Matrix
14.3. Best Practices for Companies
15. MicroRNA Therapies Market – Key Company List by Country Premium
16. MicroRNA Therapies Market - Company Analysis
16.1. Thermo Fisher Scientific, Inc.
16.2. Regulus Therapeutics
16.3. Horizon Discovery Ltd.
16.4. QIAGEN
16.5. GeneCopoeia
16.6. New England Biolabs
16.7. Quantabio
16.8. BioGenex
16.9. SeqMatic LLC
16.10. Sistemic Scotland Limited
"Financials to the Private Companies would be provided on best-effort basis."Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.
The MicroRNA Therapies Market is projected to grow at 12.5% CAGR during the forecast period 2024-2030.
Global MicroRNA Therapies Market size is estimated to be $2.5 billion in 2023 and is projected to reach $7 billion by 2030.
The leading players in the MicroRNA Therapies Market are Thermo Fisher Scientific, Inc., Regulus Therapeutics, Horizon Discovery Ltd., QIAGEN, GeneCopoeia and others.
Personalized Medicine and Biomarker Discovery, Collaboration and Partnerships and Expansion of Therapeutic Indications are some of the major MicroRNA Therapies Market trends in the industry which will create growth opportunities for the market during the forecast period.
Advancements in Molecular Biology and Genomics and Technological Advancements in RNA-based Therapeutics are the driving factors of the market.